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Abstract
Background: Estimates of excess risk of valvular heart disease among prior users of fenfluramine
and dexfenfluramine have varied widely. Two major forms of bias appear to contribute to this
variability and also result in a systematic under-estimation of risk. The first, a form of nondifferential
misclassification, is the result of including background, prevalent cases among both exposed and
unexposed persons in calculations of risk. The second bias results from not considering the
relatively short duration of exposure to drugs.
Methods: We examined data from all available echocardiographic studies reporting the prevalence
of aortic regurgitation (AR) and mitral regurgitation (MR) among persons exposed to fenfluramine
or dexfenfluramine and a suitable control group. We also included one study in which previously
existing AR or MR had been excluded. We corrected for background prevalent cases, estimated
incidence rates in unexposed persons, and performed a person-years analysis of apparent incidence
rates based on exposure time to provide an unbiased estimate of relative risk.
Results: Appearance of new AR was strongly related to duration of exposure (R2 = 0.75, p <
0.0001). The summary relative risk for mild or greater AR was 19.6 (95% CI 16.3 – 23.5, p <
0.00001); for moderate or greater MR it was 5.9 (95% CI 4.0 – 8.6, p < 0.00001).
Conclusion:  These findings provide strong support for the view that fenfluramine and
dexfenfluramine are potent causal factors in the development of both aortic and mitral valvular
heart disease.
Background
Since the initial report by Connolly, et al [1] of valvulop-
athy in women taking the combination of fenfluramine
and phentermine (fen-phen), controversy has surrounded
the issue of associated risk. Initial reports of remarkably
high prevalence of aortic and mitral regurgitation (AR and
MR) as assessed by echocardiography in five separate pop-
ulations [2] were subsequently supported by most [3–5]
but not all investigators [6]. These uncontrolled reports
were soon followed by a series of studies in which preva-
lence of echocardiographically-defined AR and MR were
assessed in persons who had taken fenfluramine, dexfen-
fluramine, phentermine, or combinations of these medi-
cations and compared to unexposed, matched control
populations [7–15]. The most recent of these studies
found 30% of persons currently taking fenfluramine or
dexfenfluramine had mild or greater AR or moderate or
greater MR, similar to the very high prevalence reported in
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older studies [15]. The only prospective study found a sig-
nificant, exposure-related increase in the risk of clinically
diagnosed valve disease among users of fenfluramine and
dexfenfluramine, but not phentermine [16].
Some recent reviews conclude that the risks associated
with fenfluramine and dexfenfluramine are similar, real
but modest for aortic valve disease, and barely detectable
for mitral valve disease; phentermine appears not to be
associated with increased risk [17–20]. Nevertheless,
interpretation of the results of these studies has been so
varied that some authors have even questioned any causal
relationship for fenfluramine exposure [21]. However,
analyses to date have not formally considered major
biases that would act to deflate the actual risk associated
with fenfluramine use. Most investigators have calculated
only prevalence ratios or prevalence odds ratios, dividing
the prevalence or odds of valve disease in exposed persons
by prevalence or odds in an unexposed control group.
This approach contrasts with a prospective design wherein
relative risk is calculated using only newly arising (inci-
dent) cases and with conventional case-control studies in
which an estimate of relative risk (the odds ratio) can be
made. If persons with prior valve disease are included in
both the exposed and the unexposed groups, a gross
underestimate of actual risk may occur. The dilution in
estimated risk is likely to be particularly important if the
background prevalence among unexposed persons is sub-
stantial but the incidence of new cases during the observa-
tion period is small, as illustrated in figure 1. While other
investigators have noted this potentially large bias [22],
no attempts at appropriate correction have been made.
A further source of under-estimated risk in prior studies is
the lack of consideration given to the time element. In a
typical prospective study, both the exposed and unex-
posed groups are generally followed for an equal period of
time. However, no prior echocardiographic study examin-
ing anorexic drug-associated valve disease has considered
the fact that measurable differences in prevalence have
arisen among persons exposed to these drugs over a
remarkably short period of time (usually a few months)
whereas the prevalent valve disease in the comparison
groups likely arose over a number of years or even a
lifetime.
In this meta-analysis, we estimated incidence rates based
on duration of drug exposure and compared these to
expected incidence rates in order to obtain unbiased esti-
mates of relative risk for the development of AR and MR.
Methods
Study Search, Selection, and Data Extraction
We first sought to identify all published studies with
echocardiographic assessment of cardiac valve regurgita-
tion in persons exposed to fenfluramine or dexfenflu-
ramine and in suitable controls. The search for studies
included examination of prior meta-analyses and reviews,
MEDLINE search (using the terms fenfluramine or dexfen-
fluramine, diet drugs, echocardiogram or echocardio-
graphic, and valvular heart disease), and review of
references of identified articles. For this analysis we
included only studies that reported duration of medica-
tion use. In some studies, results were reported separately
by duration of exposure. Each duration group was consid-
ered as a separate observation if number of persons
exposed, number of cases observed, and duration of expo-
sure was reported.
Data Synthesis
We first evaluated studies reporting echocardiographic
prevalence of FDA-positive valvulopathy (mild or greater
AR and moderate or greater MR) [2] among subjects who
had taken either fenfluramine or dexfenfluramine (alone
or in combination with phentermine) and in matched
controls [7–14]. In most of these studies, echocardio-
grams were performed after the drugs had been discontin-
ued and were read without knowledge of prior drug
exposure by multiple readers (table 1). In some studies,
control subjects were derived from patients assigned to
placebo in a formal randomized trial of fenfluramine or
dexfenfluramine. In others, controls matched for age, gen-
der and BMI were recruited and examined.
In a true prospective study, persons with valvulopathy at
baseline would be excluded from follow-up or calculation
of incidence rates. Since only one study had performed
echocardiography on a substantial number of subjects
prior to initiation of the diet drugs [11], some means of
estimating and correcting for the baseline prevalence in
the other studies was necessary. For this analysis we have
used the unexposed control groups for each study to pro-
vide such an estimate. Thus, the prevalence rate in the
control (unexposed) group of each study was used to esti-
mate the number of background cases expected in the
exposed group(s). Any cases observed beyond this back-
ground number were considered "new" or incident cases.
This approach is mathematically equivalent to modelling
the rate of change in prevalence in the exposed group with
the control group providing the initial estimate of preva-
lence. The concept is illustrated in figure 2 using data from
Jollis, et al [13]. Duration of drug use provided the time
factor to estimate incidence in the exposed groups. Two
studies which did not report duration of drug exposure
were therefore excluded from this meta-analysis [15,23].
Of major importance in this analysis is the estimation of
the expected incidence rate of FDA-positive AR and MR
(for estimation of relative risk). The most straightforward
estimate of incidence would require a sample of personsBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/5
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from the general population having no AR or MR at base-
line and who had a repeat echocardiogram some time in
the future. While two studies performed echocardiograms
one year apart in sizable populations, both showed either
no net progression or a net decrease in regurgitation in the
unexposed, control groups [24,25]. These findings under-
score the infrequency of new onset, FDA-positive AR or
MR in the unexposed population.
As an alternative estimate of expected incidence we mod-
elled change in prevalence in two populations. In the first,
data from the Framingham study were utilized [26]. In
that study, the prevalence of FDA-positive AR or MR in
persons under age 40 was zero. The prevalent cases in the
following decade (ages 40–49) were therefore assumed to
have arisen since age 40. For each subsequent decade, the
increase in prevalence was assumed to have arisen since
the prior decade. Additional assumptions were that inci-
dent cases did not drop out (that is, there was no differen-
tial mortality and change in prevalence was the result of
cumulative incidence), that incidence rates were constant
within decades, and that there was no cohort effects (i.e.,
that incidence rates in older individuals when they were
young were similar to the incidence rates in currently
young individuals). Given theses assumptions, the change
in prevalence is given by the expression
1 - (1 - i)t
Effect of adding cases from competing causes on the odds ratio in a case control study Figure 1
Effect of adding cases from competing causes on the odds ratio in a case control study. In this hypothetical example of 500 
exposed and 500 unexposed persons, when no extra cases were added (far left) there were 18 cases of disease in the exposed 
and 2 cases among the unexposed yielding an odds ratio of 9.30 (p value = 0.0007). Adding an equal number of cases due to 
unrelated causes to both the exposed and unexposed groups results in dilution of the odds ratio. The odds ratio drops below 
2 after 16 cases are added and becomes non-significant after 21 cases are added (representing just 4.2% of exposed or unex-
posed groups).
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were i is the incidence rate per year and t is the number of
years between prevalence data points (10 for full dec-
ades). The equation was solved for i given the observed
change in prevalence between decades and time elapsed
(using the end of each time period). Incidence rates were
calculated for FDA-positive AR and MR separately for each
decade in men and women. These estimated incidence
rates are shown in table 2. As a conservative estimate for
relative risk calculations, all the rates were pooled (as the
unweighted mean of the calculated rates in table 2 for
men and women), recognizing that this will yield a higher
"unexposed" rate than was likely present for the younger
and predominantly female populations exposed to the
anorexic drugs. The average estimated Framingham inci-
dence rates for age 40 and over calculated in this manner
Table 1: Controlled prevalence studies. Each of the studies compared the prevalence of aortic (mild or greater) and mitral (moderate 
or greater) regurgitation in a series of patients exposed to either fenfluramine or dexfenfluramine. Only studies reporting duration of 
exposure to these drugs are included here. A single study excluded prior valve disease by baseline echocardiograms and is also included. 
Controls were generally recruited matching for age, gender, height and weight.
First author, year Study design, echocardiography, comments
Khan, 1998 Exposed patients participated in one of 3 studies at a medical center. One study used 30–60 mg fenfluramine with phentermine 
30 mg/day (exposure duration 26.5 months). The other two studies used dexfenfluramine 30 mg/day (one without phentermine, 
exposure duration 4.9 months; the other allowed phentermine 30 mg/day, exposure duration 9 months). Controls were 
recruited later, matched to sex, age, height, BMI.
Echocardiographers were apparently unblinded with regard to patient status. The first reader was blinded for all but potentially 
60 exposed cases. All films were read by a second reader. A third reader was used if the 1st and 2nd reader did not agree. Good 
concordance reported
Weissman, 1998 Participants were in a randomized, placebo-controlled trial comparing dexfenfluramine, sustained-release dexfenfluramine, and 
placebo. Original protocol was for 16 weeks but was stopped prematurely due to withdrawal of fenfluramine and dexfenflu-
ramine from market. Blinding maintained and echocardiography scheduled soon after stopped. Investigators and patients 
remained blinded to treatment.
Standardized protocol. Echocardiographers were unaware of patient status. Echocardiograms read at an independent reading 
center. Scans were-re-read if any valve abnormality seen. 5% of scans read by other readers to judge reproducibility. Excellent 
reproducibility.
Shively, 1999 26 sites were to supply 5 or more cases who had taken dexfenfluramine (no other anorexic) for at least 3 months and 5 or 
more controls (matched by age, gender, and BMI) who had used no anorexics for 5 or more years.
Echocardiographers (at centers near each site) were blinded to subject status. There were three blinded readers (2 of 3 readers 
had to agree or re-reading required). Good inter-reader agreement reported.
Hensrud, 1999 Participants of a small, double-blind, randomized trial assigned to either fen-phen or placebo. Echocardiograms read by a blinded 
reviewer.
Ryan, 1999 Patients were enrolled in a long-term research study with fenfluramine (and some with dexfenfluramine) with baseline echocar-
diograms. 86 patients were re-scanned after fenfluramine and dexfenfluramine were withdrawn. 7 of these (8.1%) had pre-exist-
ing regurgitation and are eliminated in this analysis.
Good inter- and intra-reader concordance was demonstrated for baseline and follow-up echocardiograms. Readings were 
blinded as to order (baseline versus follow-up) of echocardiograms.
Gardin, 2000 Investigators at 25 centers who had frequently prescribed dexfenfluramine or fen-phen and could enroll subjects were invited to 
participate. Initially, controls were matched on 4 criteria (age, sex, BMI, and geographical area), then less stringent geographic 
criteria were implemented.
Standardized protocol. Echocardiographers were blinded with regard to patient treatment status. Echocardiograms were read 
blind at a core lab. Good inter- and intra-reader concordance reported.
Jollis, 2000 33 practices with large numbers of prescriptions were invited to participate. Required 3 months+ treatment with fen-phen. 
Matched controls from same centers. Dyspnea on exertion more frequent in drug group. SSRI use was not associated with AR 
or MR.
Standardized protocol. Readers blinded to treatment status. Good agreement in 350 scans read by 2 or more cardiologists.
Davidoff, 2001 Female smokers who had participated in a double-blind placebo-controlled trial of fenfluramine for smoking cessation were con-
tacted approximately 4.5 years after the study was completed to undergo echocardiography.
Standardized protocol. Echocardiographers were blinded to patient history. Tapes read at central lab. Re-reading performed 
when abnormalities present. Good inter-reader agreement reported.BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/5
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a. Prevalence of mild or greater aortic regurgitation by duration of exposure compared with controls Figure 2
a. Prevalence of mild or greater aortic regurgitation by duration of exposure compared with controls. Adapted from data pre-
sented in Jollis, et al (reference [13]). b. Rationale for present study using data from figure 2a. The controls are considered to 
provide an estimate of the background or baseline risk of AR prior to exposure (shown in dark grey). Prevalent cases beyond 
this estimated background rate were considered to have arisen during the period of drug exposure, thus providing an estimate 
of incidence (white portion of bars).
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were 0.357% per year for mild or greater AR and 0.143%
per year for moderate or greater MR.
The second data set used to estimate unexposed incidence
rates was the control groups of the studies listed in table
1. Cases of FDA-positive AR and MR reported in the con-
trol groups were assumed to have arisen between age 40
and the average age of the control group in each study. A
mean of the estimated incidence from each study was
calculated and weighted by the number of controls per
study. Since FDA-positive AR and MR are found in other
populations under age 40 [27], the assumption that all the
observed AR and MR occurred only after age 40 will result
in conservatively high estimates of incidence (resulting in
lower estimates of relative risk).
The observed number of "incident" cases of AR or MR in
the exposed group was calculated as the total number of
cases minus the number expected at baseline (estimated
from the prevalence in the unexposed control group in
each study). Any negative numbers were set to 0 (one
instance of AR with under 3 months exposure). The
expected number of cases in the exposed population (for
Poisson analyses) was calculated as the incidence rate (per
year) determined from the pooled rate in controls
(obtained as described above) multiplied by the duration
of exposure (in years). The probability of observing the
number of "incident" cases in the exposed group of each
individual study given the number expected from the
pooled estimate was calculated using a Poisson distribu-
tion. Confidence intervals for the percent of incident cases
during each study (figures 3 and 4) were calculated as sug-
gested by Fleiss for observed versus expected proportions
[28]. Effect of exposure duration and other factors on per-
cent of incident cases during each study was tested in a
weighted analysis of covariance using the GLM procedure
in SAS (SAS Institute, Carey, North Carolina).
Relative risks were calculated as (incident cases / person-
years in exposed) / (cases in controls / person-years in
controls). Person-years in the exposed group were calcu-
lated as: (total number exposed – cases expected at base-
line) × (mean duration of drug use reported for each
study). Person-years in unexposed controls were
calculated as: (total number in the control group) × (the
number of years from age 40 to the average age of the
group). Note that pooled incidence rates for the unex-
posed were not used in this analysis (so as not to inflate
power); rather, each study provided its own estimates. Sig-
nificance and confidence intervals for the relative risks
were calculated as suggested by Kleinbaum, et al [29] for
a density type follow-up study. This approach tests the
difference in incidence between two groups given that fol-
low-up time may be different in the exposed and unex-
posed populations.
Table 2: 2a. Aortic regurgitation incidence (percent per year) estimated from Framingham Study prevalence (Singh, et al, 1999). 
Prevalence of mild or greater aortic regurgitation utilized.
Men Women
Age N Prevalence (%) Incidence N Prevalence (%) Incidence
26–39 91 0 - 93 0 -
40–49 352 1.7 0.171 451 0.7 0.070
50–59 433 4.2 0.253 515 2.1 0.141
60–69 359 12.7 0.884 390 6.8 0.480
70–83 91 14.4 0.132 90 16.9 0.816
2b. Mitral regurgitation incidence estimated from Framingham Study prevalence rates (Singh, et al, 1999). Prevalence of moderate or greater mitral 
regurgitation utilized.
Men Women
Age N Prevalence (%) Incidence N Prevalence (%) Incidence
26–39 91 0 - 93 0 -
40–49 351 0.3 0.030 452 0.9 0.090
50–59 432 1.6 0.131 515 1.0 0.010
60–69 372 2.4 0.080 395 2.3 0.131
70–83 90 11.2 0.706 90 0.0 0.000BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/5
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Results
Raw data from each study is given for mild or greater AR
in table 3 and for moderate or greater MR in table 4.
Estimates of unexposed incidence of AR and MR utilizing
data from the control groups in these studies yielded val-
ues approximately 50% higher than estimates from the
Framingham study; 0.555% per year for mild or greater
AR and 0.219% per year for moderate or greater MR. To
provide conservative estimates of relative risk, these rates
were used to calculate the expected number affected
(given the duration of exposure in each study) for Poisson
analyses in tables 5 and 6. Estimates of "incident" cases
and relative risks based on person-years are also given in
tables 5 and 6.
The percent of incident cases of AR during each study (cal-
culated without dividing by duration of exposure for this
analysis) was found to be clearly related to duration of
exposure. This is illustrated in figure 3. In a weighted anal-
ysis of covariance including all the studies in table 5, R2
was 0.75, suggesting that 75% of the variance between the
studies of the percent of incident cases was explained by
duration of exposure. The coefficient relating estimated
incidence to duration (in months) was 0.00720 (p <
0.0001). In contrast, time since stopping drug and dose
were not related to estimated incidence in this analysis.
All but three of the 95% confidence intervals from these
22 point estimates included the regression line, suggesting
a fairly homogeneous estimate of risk. Remarkably, the
predicted cumulative incidence after 1 year exposure was
Estimated percent of incident cases with mild or greater AR arising during the exposure period (± 95% confidence intervals)  versus duration of exposure to fenfluramine or dexfenfluramine Figure 3
Estimated percent of incident cases with mild or greater AR arising during the exposure period (± 95% confidence intervals) 
versus duration of exposure to fenfluramine or dexfenfluramine. Some studies provided multiple point estimates based on dif-
ferent exposure times. The midpoint of the duration interval was used to plot these observations. Expected incident cases 
were calculated using the pooled estimate described in the text.
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9.6%. The weighted estimate of incidence from all studies
combined (ignoring duration of exposure) was 6.29%
(95% CI 5.51% – 7.16%, z = 14.2, p < 0.00001) during a
mean exposure time of 8.78 months. This contrasts with
an expected incidence of 0.42% in 9 months at the rate
estimated from the pooled control groups of these studies.
The summary relative risk for AR was 19.6 (95% CI 16.3 –
23.5, p < 0.00001).
The percent of incidence cases of moderate or greater MR
was lower than AR in these studies. There was no signifi-
cant correlation with duration of exposure (R2 = 0.126,
regression coefficient = 0.00037, p = 0.39) or with dose or
time since stopping drug (by weighted analysis of covari-
ance using continuous variables). The percent of inci-
dence cases was marginally greater in those exposed for 3
months or more (1.30% ± 0.19, mean ± SE) compared to
those with lower exposure times (0.54% ± 0.31, p = 0.09).
Overall, estimated incidence was markedly greater than
expected in most studies as shown in figure 4 and table 6.
The weighted estimate of incidence of MR including all
studies was 1.09% (95% CI 0.78% – 1.50%, z = 5.2, p <
0.00001) during an average exposure time of 8.89 months
with an expected incidence of 0.16% in 9 months based
on the pooled control groups. The summary relative risk
for MR was 5.9 (95% CI 4.0 – 8.6, p < 0.00001).
Discussion
Prior summary estimates of risk for developing FDA-posi-
tive AR and MR have been based on simple comparisons
of prevalence in persons exposed and unexposed to
anorexic drugs. For example, without making any adjust-
ments to observed prevalence rates, Loke, et al [18]
reported a summary "relative risk" of 2.82 (95% CI 2.20 –
Estimated percent of incident cases with moderate or greater MR arising during the exposure period (± 95% confidence inter- vals) versus duration of exposure to fenfluramine or dexfenfluramine Figure 4
Estimated percent of incident cases with moderate or greater MR arising during the exposure period (± 95% confidence inter-
vals) versus duration of exposure to fenfluramine or dexfenfluramine.
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3.61, z = 8.21, p < 0.0001) for FDA-positive AR and 1.55
(95% CI 1.06 – 2.25, z = 2.28, p = 0.02) for MR utilizing
most of the same studies included in the present report.
Our findings suggest that these estimates are strongly
biased toward the null because of counting background,
prevalent cases as incident cases in both exposed and
unexposed groups (a form of nondifferential misclassifi-
cation) and not considering the remarkably short period
of exposure during which most observed differences in
prevalence arose. In contrast, we found much higher rela-
tive risks using methods to correct for these biases; 19.6
for AR and 5.9 for MR (both p < 0.00001). Furthermore,
our estimates of percent incident cases of AR among
Table 3: Raw data for aortic regurgitation (mild or greater). When duration of exposure was reported as a range, the midpoint of the 
range is given here. "Time off" refers to the time between the last dose of anorexic and the echocardiogram.
Author, year Mean Age Fen dose 
(mg/day)
Dexfen dose 
(mg/day)
Duration 
(months)
Time off 
(months)
Controls 
(N)
Affected in 
Controls
Exposed 
(N)
Affected in 
Exposed
Khan, 1998 46.0 90 0 26.5 3.9 233 3 163 41
43.0 0 30 4.9 3.9 39 4
44.7 0 30 9.0 3.9 31 6
Weissman, 1998 45.1 0 30 2.4 1.3 330 12 671 36
Shively, 1999 50.0 0 30 6.9 8.5 189 4 223 14
Hensrud, 1999 42.0 40 0 9.6 1.5 11 1 19 5
Ryan, 1999 49.1 60 30 16.7 12.2 0 0 79 13
Gardin, 2000 46.9 46 0 2.0 6.8 536 22 48 2
46.9 46 0 4.5 6.8 115 15
46.9 46 0 9.0 6.8 117 13
46.9 46 0 15.0 6.8 86 14
46.9 46 0 22.0 6.8 85 18
48.4 0 29 2.0 5.3 92 0
48.4 0 29 4.5 5.3 183 15
48.4 0 29 9.0 5.3 166 23
48.4 0 29 15.0 5.3 29 4
Jollis, 2000 46.1 60 0 2.0 15 669 24 25 1
46.1 60 0 4.5 15 313 14
46.1 60 0 9.0 15 415 29
46.1 60 0 18.0 15 315 43
46.1 60 0 30.0 15 86 15
Davidoff, 2001 48.8 60 0 2.5 53 254 11 276 17
Table 4: Raw data for mitral regurgitation (moderate or greater). When duration of exposure was reported as a range, the midpoint 
of the range is given here. "Time off" refers to the time between the last dose of anorexic and the echocardiogram.
Author, year Mean Age Fen dose 
(mg/day)
Dexfen dose 
(mg/day)
Duration 
(months)
Time off 
(months)
Controls 
(N)
Affected in 
Controls
Exposed 
(N)
Affected in 
Exposed
Khan, 1998 45.3 90 30 20.6 3.9 233 0 233 2
Weissman, 1998 45.1 0 30 2.4 1.3 333 4 677 12
Shively, 1999 50.0 0 30 6.9 8.5 189 1 223 3
Hensrud, 1999 42.0 40 0 9.6 1.5 11 0 19 0
Ryan, 1999 49.1 60 30 16.7 12.2 0 0 79 1
Gardin, 2000 46.9 46 0 11.9 6.8 537 17 452 23
Gardin, 2000 48.4 0 29 6 5.3 472 23
Jollis, 2000 46.1 60 0 2 15 668 10 25 0
46.1 60 0 4.5 15 313 7
46.1 60 0 9 15 412 12
46.1 60 0 18 15 315 8
46.1 60 0 30 15 86 2
Davidoff, 2001 48.8 60 0 2.5 53 254 12 276 14BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/5
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Table 5: Estimated incidence rates and relative risks for mild or greater AR. The number of expected cases were based on estimated 
incidence rates utilizing the pooled control (unexposed) groups of these studies. Relative risks and z statistics were calculated within 
each study.
Author, year Duration 
(months)
"Incident" 
cases
Expected 
cases
p-value by 
Poisson
Relative 
Risk (RR)
Lower 95% 
CI of RR
Upper 95% 
CI of RR
zp - v a l u e
Khan, 1998 26.5 38.9 1.939 <0.00001 59.5 31.6 112.1 12.7 <0.00001
4.9 3.5 0.086 <0.00001 69.1 31.1 153.4 10.4 <0.00001
9.0 5.6 0.125 <0.00001 108.0 57.1 204.4 14.4 <0.00001
Weissman, 1998 2.4 11.6 0.696 <0.00001 15.3 8.4 27.9 8.9 <0.00001
Shively, 1999 6.9 9.3 0.685 <0.00001 38.4 18.9 78.0 10.1 <0.00001
Hensrud, 1999 9.6 3.3 0.075 <0.00001 7.8 1.2 51.8 2.1 0.016
Ryan, 1999 16.7 13 0.600 <0.00001 - - - - -
Gardin, 2000 2.0 0.03 0.042 0.96 0.7 0.0 61295 -0.1 0.52
4.5 10.3 0.226 <0.00001 47.8 31.3 73.0 17.9 <0.00001
9.0 8.2 0.459 <0.00001 18.8 10.6 33.3 10.0 <0.00001
15.0 10.5 0.563 <0.00001 19.5 11.6 32.9 11.2 <0.00001
22.0 14.5 0.816 <0.00001 18.7 11.6 30.0 12.1 <0.00001
2.0 0 0.080 0.92 0.0 0.0 - -0.3 0.60
4.5 7.5 0.359 <0.00001 26.1 15.0 45.2 11.6 <0.00001
9.0 16.2 0.652 <0.00001 31.0 20.6 46.7 16.5 <0.00001
15.0 2.8 0.190 0.0010 18.5 7.6 45.1 6.4 <0.00001
Jollis, 2000 2.0 0.10 0.022 0.022 5.1 0.0 1233 0.6 0.28
4.5 2.8 0.618 0.026 4.8 1.6 14.9 2.8 0.0029
9.0 14.1 1.638 <0.00001 9.3 5.4 15.9 8.1 <0.00001
18.0 31.7 2.486 <0.00001 13.8 9.2 20.6 12.7 <0.00001
30.0 11.9 1.131 <0.00001 11.4 6.6 19.7 8.7 <0.00001
Davidoff, 2001 2.5 5.0 0.300 <0.00001 20.8 9.9 43.4 8.1 <0.00001
Summary, 2002 8.78 220.8 14.01 <0.00001 19.6 16.3 23.5 31.7 <0.00001
Table 6: Estimated incidence rates and relative risks for moderate or greater MR. The number of expected cases were based on 
estimated incidence rates utilizing the pooled control (unexposed) groups of these studies. Relative risks and z statistics were calculated 
within each study. No cases of MR were observed in unexposed groups of the Khan and Hensrud studies making relative risks 
inestimable. These studies did contribute to the summary estimates.
Author, year Duration 
(months)
"Incident" 
MR cases
Expected 
cases
p-value by 
Poisson
Relative 
Risk (RR)
Lower 95% 
CI of RR
Upper 95% 
CI of RR
zp - v a l u e
Khan, 1998 20.6 2.00 0.873 0.059 - - - 2.7 0.0033
Weissman, 
1998
2.4 3.87 0.289 0.00023 14.9 5.2 42.5 5.0 <0.00001
Shively, 1999 6.9 1.82 0.279 0.032 29.7 6.2 142.8 4.2 0.000012
Hensrud, 1999 9.6 0.00 0.033 0.97 - - - - -
Ryan, 1999 16.7 1.00 0.241 0.025 - - - - -
Gardin, 2000 11.9 8.69 0.950 <0.00001 5.0 2.4 10.4 4.3 <0.00001
6 8.06 0.500 <0.00001 10.5 5.3 20.5 6.8 <0.00001
Jollis, 2000 2 0.00 0.009 0.99 0.0 0.0 - -0.1 0.54
4.5 2.31 0.253 0.0022 9.5 3.0 30.5 3.8 0.000079
9 5.83 0.666 0.000069 9.1 3.9 21.1 5.1 <0.00001
18 3.28 1.018 0.020 3.3 1.0 10.8 2.0 0.022
30 0.71 0.463 0.37 1.6 0.1 17.3 0.4 0.35
Davidoff, 2001 2.5 0.96 0.120 0.11 3.6 0.5 25.3 1.3 0.096
Summary, 2002 8.89 38.5 5.7 <0.00001 5.9 4.0 8.6 9.1 <0.00001BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/5
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exposed were highly correlated with duration of exposure
and appeared homogeneous, suggesting a biologically rel-
evant, strong, causal relationship.
Are these high estimates of risk unprecedented? In the
only true prospective study comparing risk in exposed and
unexposed persons, Jick, et al [16] identified clinically
diagnosed valvular disease using the large UK General
Practice Research Database. Using the data provided in
the paper, a valve-specific analysis may be performed
comparing incidence of aortic and mitral disease in those
exposed for 4 months or longer versus all others. The
results reveal a relative risk of 17.1 for AR and 34.3 for MR,
both with p < 0.0001 by chi-square. Since the few cases
that arose within 3 months of exposure are included in the
"unexposed" group in this analysis, even these high risks
represent an underestimate. Nevertheless, the close simi-
larity in the estimate of AR relative risk to the present
study is remarkable. The much higher risk for MR com-
pared to our estimate may represent fundamental biolog-
ical differences between clinically apparent valve disease
and echocardiographically assessed valve disease.
A single study among those reviewed in our meta-analysis
excluded persons with valve disease using echocardio-
grams taken prior to starting drug [11]. That study yielded
estimates of AR and MR incidence that were similar to our
summary estimates, further supporting our findings. The
fact that so many studies have observed statistically signif-
icant differences in prevalence after relatively short expo-
sure to drug suggest that underlying incidence rates of new
valvulopathy must be extraordinarily high compared to
the expected low unexposed rate.
Data provided in this study can be used to estimate the rel-
ative contribution of exposure to fenfluramines to overall
incidence of echocardiographically defined, FDA-positive
AR and MR. Given that approximately 2.5% of the popu-
lation of the United States had used anorexic prescription
drugs (mostly fenfluramine and dexfenfluramine)
between 1996 and 1998 [30], approximately 32% and
11% of all FDA-positive AR and MR respectively could be
attributed to fenfluramine or dexfenfluramine use.
Among those who had actually taken the drugs, the attrib-
utable fraction rises to 95% and 83% for AR and MR
respectively.
Why was there no apparent effect of exposure duration on
MR incidence? This may well be due to low power. If only
0.25 of an incident case had been seen in the exposed
group of Hensrud, et al [10] and 1 extra case had been
seen in the group exposed 30 months in Jollis, et al [13]
then a significant logarithmic relationship between dura-
tion and percent incident cases would have become
apparent, illustrating the precarious nature of correlations
when events are few. While we cannot claim such a rela-
tionship does exist, the relatively low incidence seen gen-
erally for moderate or greater MR makes establishing
strong correlations difficult. Importantly, we cannot
conclude that a positive association between exposure
duration and incident MR does not exist, only that the
current studies are inconclusive regarding this relation-
ship. We can conclude, however that the current studies
provide sufficient power in aggregate to clearly demon-
strate an overall excess risk for developing MR.
Another approach to expressing excess risk is the calcula-
tion of "number needed to harm" (NNH). NNH may be
calculated as the inverse of the difference between risk in
exposed and risk in unexposed persons. For example, the
cumulative prevalence of AR was 95.6 per 1000 in those
exposed to fenfluramines without regard to exposure time
(342 cases among 3576 exposed, from table 3) compared
to 34.7 per thousand among unexposed (77 cases among
2222 unexposed) for a NNH of 16.4. For MR, the cumu-
lative prevalence was 29.9 per 1000 in exposed (107 of
3582 exposed, from table 4) versus 19.8 per thousand (34
of 2225 exposed) for a NNH of 99. A risk difference, as
used to calculate NNH, is less subject to nondifferential
misclassification than is a risk ratio. However, demon-
strating association with graded exposures and statistical
methods to determine significance or confidence intervals
are well defined for relative risk but not for NNH. We have
therefore emphasized estimates of relative risk. Impor-
tantly, estimates of NNH as calculated by differences
between exposed and unexposed prevalence rates, shown
above, were very similar to NNH determined using differ-
ences between our estimated 9-month incidence rates in
exposed and unexposed (NNH was 17 for AR and 108 for
MR by this approach), further illustrating the internal con-
sistency of our analysis.
Our study has several limitations. There is no direct meas-
ure of true incidence of AR or MR in the unexposed
population. The only studies to perform repeated echocar-
diograms (separated by one year in both) in large
numbers of unexposed persons found either no net pro-
gression or net regression in their control groups [24,25].
Because these studies did not report usable direct meas-
ures of incidence, we made several assumptions to esti-
mate unexposed incidence using raw data from the
Framingham study and from the studies reviewed here.
Our observation that incidence rates estimated from both
populations were of a similar magnitude supports the fea-
sibility of this approach. Further, our estimate is conserv-
ative. For example, using the Framingham estimates
would have yielded 50% higher relative risks. Had we sub-
tracted the prevalence of FDA-positive AR (1.2%) and MR
(1.0%) seen in the CARDIA study [27] and considered the
time course of new valve disease development to com-BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/5
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mence at age 35 (the ending age of the CARDIA study),
the unexposed incidence would have been approximately
half the rate we used and the relative risks doubled.
Our estimate of apparent incidence of AR and MR among
the exposed groups is also based on several assumptions.
However, the strong, consistent relationship between the
percent of incident cases of AR in each study and duration
of exposure suggests that our estimates were reasonable
and biologically relevant. We acknowledge that there were
a number of differences between the study groups
included in our analysis. There were differences in study
design and methods (though most were quite similar),
fenfluramine or dexfenfluramine doses (though in most
studies, doses were similar), additional drugs used,
patient characteristics, interval between cessation of ther-
apy and echocardiography, and completeness of follow-
up. However, these differences would likely add random
error and therefore decrease any observed correlation. Esti-
mates of incidence among unexposed controls from each
study were more variable, resulting in greater differences
between studies in estimates of relative risk. This is not
surprising considering the relatively rare occurrence of
new onset AR or MR in unexposed middle-aged men and
women.
We have not formally considered other potential sources
of bias in our analyses. These include measurement bias
(related to acquisition and reading of echocardiograms)
[22], selection bias (particularly in studies with incom-
plete follow-up) [31], and potential reversibility of valvu-
lopathy [10,24,25,32]. If a reversible component occurred
rather quickly after stopping drugs, then one might expect
a stable, lower prevalence in studies performed well after
drugs were stopped, with no relationship between preva-
lence of valve dysfunction and time off medication.
Indeed, the most recently published study (which did not
suffer from measurement bias) showed a high prevalence
(30%) of AR in persons taking fenfluramine or dexfenflu-
ramine at the time of the echocardiogram, similar to the
older prevalence studies [15]. Regarding the potential
reversibility of valve dysfunction, great caution must be
exercised in assuming any substantial reversal of valvular
plaques, as recent pathological studies suggest a progres-
sive nature to these lesions [33]. Furthermore, limited,
early apparent echocardiographic improvement of acute
rheumatic carditis has also been recently demonstrated
[34]. The early improvement seen in this setting certainly
does not preclude later progression of rheumatic valvular
heart disease.
In conclusion, we have estimated risks associated with use
of fenfluramine or dexfenfluramine for developing FDA-
positive AR and MR after correcting for two major sources
of bias. Accordingly, our estimates of relative risk associ-
ated with fenfluramine or dexfenfluramine use, 19.6 for
AR and 5.9 for MR, are higher than in prior reviews. These
findings lend strong support to the view that fenfluramine
and dexfenfluramine are potent causal factors in the
development of both aortic and mitral valvular heart
disease.
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